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A BS TR AC T
BACKGROUND
Among patients with acute ischemic stroke due to occlusions in the proximal ante-
rior intracranial circulation, less than 40% regain functional independence when 
treated with intravenous tissue plasminogen activator (t-PA) alone. Thrombectomy 
with the use of a stent retriever, in addition to intravenous t-PA, increases reperfu-
sion rates and may improve long-term functional outcome.
METHODS
We randomly assigned eligible patients with stroke who were receiving or had re-
ceived intravenous t-PA to continue with t-PA alone (control group) or to undergo 
endovascular thrombectomy with the use of a stent retriever within 6 hours after 
symptom onset (intervention group). Patients had confirmed occlusions in the proxi-
mal anterior intracranial circulation and an absence of large ischemic-core lesions. 
The primary outcome was the severity of global disability at 90 days, as assessed by 
means of the modified Rankin scale (with scores ranging from 0 [no symptoms] to 
6 [death]).
RESULTS
The study was stopped early because of efficacy. At 39 centers, 196 patients under-
went randomization (98 patients in each group). In the intervention group, the 
median time from qualifying imaging to groin puncture was 57 minutes, and the 
rate of substantial reperfusion at the end of the procedure was 88%. Thrombectomy 
with the stent retriever plus intravenous t-PA reduced disability at 90 days over the 
entire range of scores on the modified Rankin scale (P<0.001). The rate of func-
tional independence (modified Rankin scale score, 0 to 2) was higher in the inter-
vention group than in the control group (60% vs. 35%, P<0.001). There were no 
significant between-group differences in 90-day mortality (9% vs. 12%, P = 0.50) or 
symptomatic intracranial hemorrhage (0% vs. 3%, P = 0.12).
CONCLUSIONS
In patients receiving intravenous t-PA for acute ischemic stroke due to occlusions in 
the proximal anterior intracranial circulation, thrombectomy with a stent retriever 
within 6 hours after onset improved functional outcomes at 90 days. (Funded by 
Covidien; SWIFT PRIME ClinicalTrials.gov number, NCT01657461.)
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Intravenous tissue plasminogen acti-vator (t-PA) administered within 4.5 hours after the onset of acute ischemic stroke im-
proves outcomes.1-3 However, intravenous t-PA has 
multiple constraints, including unresponsiveness 
of large thrombi to rapid enzymatic digestion, a 
narrow time window for administration, and the 
risk of cerebral and systemic hemorrhage. Among 
patients with occlusions of the intracranial inter-
nal carotid artery or the first segment of the 
middle cerebral artery (or both), intravenous t-PA 
results in early reperfusion in only 13 to 50%.4-7
Neurovascular thrombectomy is a reperfusion 
strategy that is distinct from pharmacologic fibri-
nolysis. Endovascular mechanical treatments can 
remove large, proximal clots rapidly and result in 
higher rates of reperfusion than intravenous t-PA 
alone. Three initial trials of endovascular thera-
pies did not show a benefit for thrombectomy 
over intravenous t-PA or supportive medical care, 
but they were limited by the use of intraarterial 
delivery of t-PA or the use of early-generation de-
vices with modest reperfusion efficacy (or both), 
the failure of two trials to use vessel imaging to 
confirm the presence of an appropriate target oc-
clusion, and the slow initiation of endovascular 
intervention.8-10
The Solitaire revascularization device (Covidien) 
is a self-expanding stent used to retrieve thrombi 
and restore blood flow. In multicenter registries 
and one randomized trial, this stent retriever, 
as compared with early-generation mechanical 
thrombectomy devices, was associated with fast-
er and more frequent reperfusion, reduced intra-
cranial hemorrhage, and improved disability 
outcome.11-15
We performed the Solitaire with the Intention 
for Thrombectomy as Primary Endovascular Treat-
ment (SWIFT PRIME) trial to establish the effi-
cacy and safety of rapid neurovascular throm-
bectomy with the stent retriever in conjunction 
with intravenous t-PA versus intravenous t-PA alone 
in patients with acute ischemic stroke. This trial 
was among several contemporaneous trials 
launched worldwide to test new-generation strat-
egies for mechanical thrombectomy.16-18 Our 
trial was conducted in multiple countries and 
health systems as a registration trial capable of 
supporting expansion of regulatory labeling. We 
used a uniform device procedure in the interven-
tion group and tested intracranial neurovascular 
thrombectomy alone rather than in combination 
with cervical stenting.
ME THODS
TRIAL DESIGN
In this international, multicenter, prospective, 
randomized, open clinical trial, we compared in-
travenous t-PA followed by neurovascular throm-
bectomy with the use of a stent retriever with 
intravenous t-PA alone in patients with acute is-
chemic stroke. All the patients had confirmed oc-
clusion of the intracranial internal carotid artery, 
the first segment of the middle cerebral artery, or 
both on vessel imaging and an absence of large 
ischemic-core lesions. Patients were randomly 
assigned in a 1:1 ratio to one of two treatment 
groups: intravenous t-PA plus stent retriever (in-
tervention group) or intravenous t-PA alone (con-
trol group). Using a minimization algorithm, 
we balanced the numbers of patients in the two 
treatment groups with respect to four factors: 
investigational site, baseline severity according 
to the National Institutes of Health Stroke Scale 
(NIHSS) score (≤17 vs. >17, on a scale of 0 to 42, 
with higher scores indicating greater severity), age 
(<70 years vs. ≥70 years), and occlusion location 
(middle cerebral artery vs. internal carotid artery).
Details of the study design have been pub-
lished previously.19 The study was conducted and 
reported with fidelity to the study protocol, avail-
able with the full text of this article at NEJM.org. 
(An overview of the study procedure is provided 
in Fig. S1 in the Supplementary Appendix, avail-
able at NEJM.org.)
The trial was approved by the institutional 
review board at each site. Enrolled patients pro-
vided written informed consent, or at select sites, 
there was an exception from explicit informed 
consent in emergency circumstances.
The trial was funded by Covidien and designed 
and led by a steering committee that included 
academic investigators and representatives of the 
sponsor. The site investigators gathered the data, 
with monitoring and database maintenance per-
formed by the sponsor. The first and subsequent 
drafts of the manuscript were written by the 
first and second authors, incorporating input 
from all the authors. The academic authors had 
unrestricted access to the data, performed the 
data analysis with the primary and the indepen-
dent study statisticians, and attest to the integ-
rity of the trial and the completeness and accu-
racy of the reported data. The trial was monitored 
by an independent data and safety monitoring 
board.
The New England Journal of Medicine 
Downloaded from nejm.org at E-Library Insel on June 9, 2015. For personal use only. No other uses without permission. 
 Copyright © 2015 Massachusetts Medical Society. All rights reserved. 
Stent Retriever after Intr avenous t-PA vs. t-PA Alone
n engl j med nejm.org 3
PATIENTS AND PARTICIPATING CENTERS
The study was performed at 39 centers in the 
United States and Europe. All study centers were 
required to have performed at least 40 mechani-
cal-thrombectomy procedures, including at least 
20 procedures with the Solitaire stent retriever, 
annually. Entry criteria selected patients who had 
acute ischemic stroke with moderate-to-severe 
neurologic deficits; had imaging-confirmed oc-
clusion of the intracranial internal carotid artery, 
the first segment of the middle cerebral artery, or 
both; met the imaging eligibility requirements; 
were receiving or had received intravenous t-PA; 
and were able to undergo initiation of endovas-
cular treatment within 6 hours after the time 
that they were last known to be well before the 
onset of acute stroke symptoms. Qualifying im-
aging had to be performed at a study hospital; im-
aging was repeated for patients who were trans-
ferred from outside hospitals. Detailed study 
inclusion and exclusion criteria are provided in 
Table S1 in the Supplementary Appendix.
To identify patients with salvageable tissue, at 
trial launch the entry criteria regarding imaging 
selection required patients to have a target-mis-
match penumbral profile, with a small core of 
tissue that was likely to be irreversibly injured 
and a large region of hypoperfused tissue that 
was likely to be salvageable. Penumbral imaging 
analysis was performed with the use of RAPID 
(iSchemaView), an operator-independent image-
postprocessing system.20 After the enrollment of 
the first 71 patients, these criteria were revised 
to use a small-to-moderate core-infarct strategy 
(Table S1 in the Supplementary Appendix) to ac-
commodate study sites with limited perfusion-
imaging capability and to ensure accelerated treat-
ment delivery. Study sites with advanced imaging 
capability were still encouraged to obtain pen-
umbral imaging and to exclude patients who did 
not meet the target-mismatch profile.
INTERVENTION
In the intervention group, neurovascular throm-
bectomy was performed with the use of the Soli-
taire FR (Flow Restoration) or Solitaire 2 device. 
Concomitant stenting of the cervical internal ca-
rotid artery was not permitted, although angioplas-
ty could be performed to permit intracranial access.
A studywide continuous quality-improvement 
program emphasized the speed and quality of the 
neurointerventional workflow, including rapid pa-
tient transfer to the neuroangiography suite and 
procedure performance. The study target for the 
time from qualifying imaging to groin puncture 
was within 70 minutes.
OUTCOME MEASURES
The primary study-outcome measure was disabil-
ity at 90 days, as assessed by means of the modi-
fied Rankin scale, a global measure of disability 
on a seven-level scale, with scores ranging from 
0 (no symptoms) to 6 (death) (Fig. 1). (Details on 
the use of this scale are provided in the Supple-
mentary Appendix.)
Secondary clinical efficacy outcomes were the 
rate of death at 90 days, the rate of functional 
independence (modified Rankin scale score, ≤2) 
at 90 days, and the change in the NIHSS score 
at 27 hours after randomization. The technical 
efficacy outcomes regarding revascularization were 
substantial reperfusion, as assessed by means of 
catheter angiography in the intervention group 
and defined as a modified Thrombolysis in Ce-
Score on Modified Rankin Scale
Stent Retriever +
Intravenous t-PA
(N=98)
Intravenous t-PA
(N=93)
Patients (%)
210 3 4 5  or 6
17 26 17 12 1215
9 11 16 17  2622
No symptoms Death
Figure 1. Functional Outcomes at 90 Days, According to the Score  
on the Modified Rankin Scale.
Shown are the 90-day scores on the modified Rankin scale for the patients 
in the two treatment groups. Scores range from 0 to 6, with 0 indicating no 
symptoms, 1 no clinically significant disability (able to carry out all usual 
activities, despite some symptoms), 2 slight disability (able to look after 
own affairs without assistance but unable to carry out all previous activi-
ties), 3 moderate disability (requires some help but able to walk unassist-
ed), 4 moderately severe disability (unable to attend to bodily needs with-
out assistance and unable to walk unassisted), 5 severe disability (requires 
constant nursing care and attention, bedridden, and incontinent), and  
6 death. Persons with a score of 0, 1, or 2 are considered to be independent 
in daily function. Neurovascular thrombectomy with the use of a stent re-
triever was associated with a significant shift in the distribution of scores 
toward lesser disability (P<0.001 by the Cochran–Mantel–Haenszel test), 
including an absolute increase of 25 percentage points in the proportion  
of patients who were functionally independent at 90 days (P<0.001). The 
term t-PA denotes tissue plasminogen activator.
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rebral Infarction score of 2b (50 to 99% reperfu-
sion) or 3 (complete reperfusion)21; and successful 
reperfusion at 27 hours in the two study groups, 
which was defined as reperfusion of 90% or 
more of the initial perfusion-lesion volume, as 
assessed by means of perfusion imaging (com-
puted tomography [CT] or magnetic resonance 
imaging [MRI]) at 27 hours after randomiza-
tion. Prespecified safety outcomes were all seri-
ous adverse events through study completion and 
symptomatic intracranial hemorrhage at 27 hours 
after randomization.
CLINICAL AND RADIOLOGIC ASSESSMENT
Clinical assessments were performed at baseline, 
27 hours after randomization, 7 to 10 days (or at 
discharge if earlier), 30 days, and 90 days. Clini-
cal evaluations included the score on the modi-
fied Rankin scale for assessing global disability 
and the NIHSS score for assessing neurologic 
deficit. Entry and outcome neurovascular images 
were assessed in a blinded manner by staff at the 
core imaging laboratories (iSchemaView for pen-
umbral and volumetric imaging and Synarc for 
parenchymal and angiographic imaging).
Table 1. Demographic and Clinical Characteristics of the Patients.*
Characteristic
Intravenous  
t-PA Alone
(N = 98)
Stent Retriever plus  
Intravenous t-PA
(N = 98)
Age — yr 66.3±11.3 65.0±12.5
Male sex — no./total no. (%) 45/96 (47) 54/98 (55)
Race — no./total no. (%)†
White 83/92 (90) 79/90 (88)
Black 8/92 (9) 10/90 (11)
Asian or other 1/92 (1) 1/90 (1)
Hispanic ethnic group — no. (%)† 7/92 (8) 8/90 (9)
NIHSS score‡
Median 17 17
Interquartile range 13–19 13–20
Prestroke score of 0 or 1 on modified Rankin scale — no./total 
no. (%)§
93/94 (99) 96/98 (98)
Medical history — no./total no. (%)
Hypertension 56/97 (58) 66/98 (67)
Diabetes mellitus 15/97 (15) 12/98 (12)
Current or past tobacco use 39/93 (42) 41/96 (43)
Atrial fibrillation 38/97 (39) 35/98 (36)
Myocardial infarction 11/97 (11) 8/98 (8)
Serum glucose — mg/dl¶ 131±47 131±46
Administration of intravenous t-PA at outside  
hospital — no./total no. (%)
35/94 (37) 31/98 (32)
Interval from symptom onset to start of intravenous t-PA — min
Median 117 110.5
Interquartile range 80–155 85–156
Parenchymal imaging variable
ASPECTS value‖
Median 9 9
Interquartile range 8–10 7–10
Penumbral imaging performed — no./total no. (%) 75/97 (77) 83/98 (85)
Target-mismatch profile — no./total no. (%)** 64/75 (85) 69/83 (83)
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Table 1 (Continued.)
Characteristic
Intravenous  
t-PA Alone
(N = 98)
Stent Retriever plus  
Intravenous t-PA
(N = 98)
Site of intracranial-artery occlusion — no./total no. (%)
Internal carotid artery 15/94 (16) 17/93 (18)
Middle cerebral artery
First segment 72/94 (77) 62/93 (67)
Second segment†† 6/94 (6) 13/93 (14)
Process time — min
Stroke onset to randomization
Median 188 190.5
Interquartile range 130–268 141–249
Stroke onset to groin puncture
Median NA 224
Interquartile range NA 165–275
Stroke onset to first deployment of stent  
retriever
Median NA 252
Interquartile range NA 190–300
Arrival in emergency department to groin  
puncture
Median NA 90
Interquartile range NA 69–120
Qualifying image to groin puncture
Median NA 57
Interquartile range NA 40–80
* Plus–minus values are means ±SD. There were no significant differences between the two groups. One patient in the 
group that received intravenous tissue plasminogen activator (t-PA) alone requested the deletion of all data. Three 
additional patients in the group that received intravenous t-PA alone (1 patient who died and 2 who withdrew) are 
missing some baseline data owing to early study exit, including data on the prestroke modified Rankin Scale score, 
the hospital site of intravenous t-PA administration, and site of intracranial-artery occlusion for all 3 patients, and 
data on sex, race, and ethnic group for 1. Data on race and ethnic group were missing for all 13 patients in France 
owing to national regulations. Data regarding the location of the arterial occlusion were missing for 7 patients be-
cause the core laboratory considered that imaging could not be assessed with complete reliability. Two patients were 
deemed by the core laboratory to not have occlusions in the internal carotid artery or the first or second segment of 
the middle cerebral artery. A total of 37 patients did not have baseline penumbral imaging performed, after a protocol 
amendment making penumbral imaging optional. Data regarding additional baseline characteristics are shown in 
Table S4 in the Supplementary Appendix. NA denotes not applicable.
† Race and ethnic group were self-reported.
‡ Scores on the National Institutes of Health Stroke Scale (NIHSS) range from 0 to 42, with higher scores indicating 
more severe neurologic deficit.
§ Scores on the modified Rankin scale for the assessment of global disability range from 0 (no symptoms) to 6 (death).
¶ To convert the values for glucose to millimoles per liter, multiply by 0.05551.
‖ The Alberta Stroke Program Early CT Score (ASPECTS) ranges from 0 to 10, with higher scores indicating a smaller 
infarct core.
** The target-mismatch profile was defined as meeting the following criteria as assessed on CT perfusion or diffusion 
imaging and perfusion MRI: the core infarct lesion measured 50 ml or less, the volume of tissue with a time to maxi-
mum delay of more than 10 seconds was 100 ml or less, and the mismatch volume was at least 15 ml and the mis-
match ratio was more than 1.8:1.0.
†† These occlusions were classified as first-segment occlusions by the treating site at the time of study entry but as sec-
ond-segment occlusions by the core imaging laboratory.
The New England Journal of Medicine 
Downloaded from nejm.org at E-Library Insel on June 9, 2015. For personal use only. No other uses without permission. 
 Copyright © 2015 Massachusetts Medical Society. All rights reserved. 
T h e  n e w  e ngl a nd  j o u r na l  o f  m e dic i n e
n engl j med nejm.org6
STATISTICAL ANALYSIS
For the primary outcome, we analyzed the score 
on the modified Rankin scale at 90 days using 
simultaneous success criteria of the overall dis-
tribution of the score (shift in disability levels) 
and the proportion of patients who were function-
ally independent. Both criteria needed to be met in 
order for the study to be declared positive. The 
statistical hypothesis on the scale shift was that 
the distribution over the entire range of scores 
(except for scores of 5 or 6, which were collapsed 
into a single group) among patients in the inter-
vention group would be more favorable than the 
distribution in the control group, as analyzed by 
means of the Cochran–Mantel–Haenszel test.
A simultaneous requirement for success was 
that the difference in the proportion of patients 
with a score of 0 to 2 nominally meet a pre-
specified minimum, which varied according to 
the final sample size at trial discontinuation or 
completion, with a larger benefit required with 
a smaller sample size (Table S2 in the Supple-
mentary Appendix). Missing final scores on the 
modified Rankin scale were handled with the 
use of the last-observation-carried-forward ap-
proach when a score was available from the 30-
day visit or the visit at 7 to 10 days. Power and 
sample size were determined with the use of the 
dual success criteria, incorporating a group se-
quential-analysis plan with five interim analyses 
for efficacy, futility, and safety. (Details are pro-
vided in Table S2 in the Supplementary Appen-
dix and in the full statistical analysis plan in the 
protocol.)
After the preliminary results of the Multi-
center Randomized Clinical Trial of Endovascu-
lar Treatment for Acute Ischemic Stroke in the 
Netherlands (MR CLEAN) and the Endovascular 
Treatment for Small Core and Anterior Circula-
tion Proximal Occlusion with Emphasis on Min-
imizing CT to Recanalization Times (ESCAPE) 
trial were reported,16,18 our data and safety moni-
toring board recommended holding enrollment, 
and the first interim efficacy analysis was per-
formed slightly early (including 196 rather than 
200 patients). In February 2015, the study was 
halted when the interim efficacy analysis showed 
that the prespecified stopping-criteria boundary 
for efficacy had been crossed. A test to determine 
whether the data across clinical sites could be 
pooled showed no evidence of heterogeneity of 
treatment effect (P = 0.73 by the Breslow–Day 
test), so pooled study results are presented. All 
P values are two-sided.
R ESULT S
CHARACTERISTICS OF THE PATIENTS
From December 2012 through November 2014, 
196 patients underwent randomization (98 in 
each group) at 39 centers in the United States and 
Europe. Reasons for exclusion are listed in Table 
S3 in the Supplementary Appendix.
The demographic and clinical characteristics 
of the two treatment groups at baseline were 
well balanced (Table 1, and Table S4 in the 
Supplementary Appendix). Figure S2 in the Sup-
plementary Appendix shows the enrollment and 
follow-up of patients in the trial.
INTERVENTION
In the intervention group, the time from symp-
tom onset to groin puncture was 224 minutes 
(interquartile range, 165 to 275), the time from 
the start of intravenous t-PA to groin puncture 
was 77 minutes (interquartile range, 50 to 142), 
and the time from study-qualifying brain imag-
ing to groin puncture was 57 minutes (interquar-
tile range, 40 to 80). In the intervention group, 
the stent retriever was deployed in 87 patients 
(89%); the reasons for nondeployment are listed 
in Table S5 in the Supplementary Appendix. Among 
these 87 patients, the median time from groin 
puncture to first deployment of the stent retriev-
er was 24 minutes (interquartile range, 18 to 33). 
General anesthesia was used in 36 patients (37%) 
in the intervention group.
PRIMARY OUTCOME
Treatment with thrombectomy with the use of 
the stent retriever met both of the simultaneous 
success criteria. Thrombectomy treatment was 
associated with a favorable shift in the distribu-
tion of global disability scores on the modified 
Rankin scale at 90 days (P<0.001 by the Cochran–
Mantel–Haenszel test, which was lower than the 
P value of 0.01 that was specified for early stop-
ping; number needed to treat for one additional 
patient to have a less-disabled outcome, 2.6). The 
shift toward better outcomes was consistent in 
direction across all the score levels of the modi-
fied Rankin scale (Fig. 1). The proportion of pa-
tients who were functionally independent (modi-
fied Rankin scale score, ≤2) at 90 days was 
The New England Journal of Medicine 
Downloaded from nejm.org at E-Library Insel on June 9, 2015. For personal use only. No other uses without permission. 
 Copyright © 2015 Massachusetts Medical Society. All rights reserved. 
Stent Retriever after Intr avenous t-PA vs. t-PA Alone
n engl j med nejm.org 7
higher in the intervention group than in the con-
trol group, with an absolute difference of 25 per-
centage points, which exceeded the 12-percent-
age-point boundary that was prespecified for 
early stopping. Results remained significant in 
sensitivity analyses that used multiple imputa-
tion and worst-case and best-case scenarios to 
account for missing data (Table S6 in the Supple-
mentary Appendix) and in analyses that were ad-
justed for imbalances in baseline prognostic fea-
tures (Table S7 and Fig. S3 in the Supplementary 
Appendix).
SECONDARY OUTCOMES
Prespecified secondary clinical efficacy outcomes 
and technical efficacy outcomes regarding revas-
cularization are shown in Table 2; additional pre-
specified and post hoc outcomes are shown in 
Tables S10 and S13 in the Supplementary Appen-
dix. The proportion of outcomes indicating func-
tional independence at 90 days was significantly 
higher in the intervention group than in the con-
trol group, with an absolute difference of 25 per-
centage points (95% confidence interval [CI], 11 to 
38) and a risk ratio of 1.70 (95% CI, 1.23 to 2.33; 
P<0.001; number needed to treat for one addi-
tional patient to be functionally independent, 
4.0). Mortality at 90 days did not differ signifi-
cantly between the intervention group and the 
control group (9% and 12%, respectively; P = 0.50).
In the intervention group, substantial reper-
fusion (50 to 99%) or complete reperfusion (100%) 
at the end of the procedure occurred in 73 of the 
83 patients (88%) who underwent placement of 
the stent retriever (Table S9 in the Supplementary 
Appendix). A total of 4 additional patients who 
Table 2. Primary and Secondary Outcomes.*
Outcome
Intravenous
t-PA Alone
(N = 98)
Stent Retriever plus 
Intravenous t-PA
(N = 98)
Risk Ratio
(95% CI) P Value
Primary outcome: score on modified Rankin 
scale at 90 days†
<0.001
No. of patients with data 93 98
Median score 3 2
Interquartile range 2–5 1–4
Secondary outcomes
Clinical efficacy outcome
Functional independence at 90 days  
— no./total no. (%)‡
33/93 (35) 59/98 (60) 1.70 (1.23–2.33) <0.001
Change in NIHSS score at 27 hr
No. of patients with data  92 97
Mean change −3.9±6.2 −8.5±7.1 <0.001
Death at 90 days — no./total no. (%)§ 12/97 (12) 9/98 (9) 0.74 (0.33–1.68) 0.50
Revascularization outcome¶
Substantial reperfusion immediately  
after thrombectomy — no./ 
total no. (%)
NA 73/83 (88) NA NA
Successful reperfusion at 27 hr —  
no./total no. (%)
21/52 (40) 53/64 (83) 2.05 (1.45–2.91) <0.001
* Plus–minus values are means ±SD. CI denotes confidence interval, and NA not applicable.
† Shown are the results of the prespecified Cochran–Mantel–Haenszel test for the shift in disability score. Similar results 
were found in the analysis of the common odds ratio (odds ratio, 2.63; 95% CI, 1.57 to 4.40; P<0.001).
‡ Functional independence was defined as a score of 0, 1, or 2 on the modified Rankin scale.
§ One patient in the group that received intravenous t-PA alone requested the deletion of all data, including vital status.
¶ Substantial reperfusion was defined as reperfusion of at least 50% and a modified Thrombolysis in Cerebral Infarction 
score of 2b (50 to 99% reperfusion) or 3 (complete reperfusion). Successful reperfusion was defined as reperfusion of 
at least 90%, as assessed with the use of perfusion CT or MRI. Data on successful reperfusion were not obtained for all 
the patients after the adoption of the protocol amendment making penumbral imaging optional.
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underwent the intervention did not have a final 
angiogram that could be assessed. Successful 
reperfusion (≥90%) at 27 hours, assessed by means 
of perfusion CT or MRI, was more frequent in the 
intervention group than in the control group (53 
of 64 patients [83%] vs. 21 of 52 [40%], P<0.001).
SAFETY
The rates of serious adverse events (36% in the 
intervention group and 31% in the control group, 
P = 0.54) and symptomatic intracranial hemor-
rhage (0% and 3%, respectively; P = 0.12) did not 
differ significantly between the treatment groups 
(Table 3, and Table S11 in the Supplementary Ap-
pendix). There was no significant between-group 
difference in the rate of all intracranial hemor-
rhage subtypes that were assessed radiologically, 
but there were numerically more subarachnoid 
hemorrhages in the intervention group than in 
the control group (four patients and one patient, 
respectively; P = 0.37). No serious adverse events 
and seven nonserious adverse events were adjudi-
cated to be device-related (Table S12 in the Sup-
plementary Appendix).
SUBGROUP ANALYSES
Within the constraints of the study sample size, 
no evidence of heterogeneity of treatment effect 
was detected in any of the eight prespecified sub-
groups (Fig. 2, and Fig. S4 in the Supplementary 
Appendix). The benefit of thrombectomy with the 
stent retriever plus intravenous t-PA over intrave-
nous t-PA alone was also observed in the pre-
specified subgroup of patients who received in-
travenous t-PA within 3 hours after symptom 
onset (P<0.001) (Table S8 in the Supplementary 
Appendix).
DISCUSSION
Our study showed that in patients with acute 
ischemic stroke with confirmed large-vessel oc-
clusions of the anterior circulation who were 
treated with intravenous t-PA, treatment with the 
stent retriever within 6 hours after symptom on-
set improved functional outcomes at 90 days. For 
every 2.6 patients who were treated, 1 additional 
patient had an improved disability outcome; for 
every 4.0 patients who were treated, 1 additional 
patient was functionally independent at 90-day 
follow-up.
These findings confirm and extend those of 
recent trials.16-18 Our trial emphasized speedy en-
dovascular therapy in patients selected by means 
of imaging, similar to the protocol used in the 
ESCAPE trial,18 and achieved onset-to-reperfusion 
Table 3. Safety Outcomes.*
Outcome
Intravenous 
t-PA Alone
(N = 97)
Stent Retriever plus 
Intravenous t-PA
(N = 98)
Risk Ratio
(95% CI) P Value
no. of patients (%)
Primary safety outcomes
Any serious adverse event at 90 days† 30 (31) 35 (36) 1.15 (0.78–1.72) 0.54
Symptomatic intracranial hemorrhage at 27 hr 3 (3) 0 0.00 (NA) 0.12
Additional safety outcomes at 27 hr
Parenchymal hematoma 7 (7) 5 (5) 0.71 (0.23–2.15) 0.57
Type 1 3 (3) 4 (4) 1.32 (0.30–5.74) 1.00
Type 2 4 (4) 1 (1) 0.25 (0.03–2.17) 0.21
Subarachnoid hemorrhage 1 (1) 4 (4) 3.96 (0.45–34.79) 0.37
* NA denotes not applicable.
† A serious adverse event was an adverse event that led to death, a life-threatening illness or injury, permanent impair-
ment of a body structure or a body function, inpatient or prolonged hospitalization, medical or surgical intervention to 
prevent permanent life-threatening illness or injury or permanent impairment to a body structure or a body function, or 
fetal distress, fetal death or a congenital anomaly or birth defect. Serious adverse events that are classified according to 
organ system are shown in Table S11 in the Supplementary Appendix. None of the serious adverse events were adjudi-
cated by the clinical-events committee to be device-related. Nonserious adverse events that were deemed to be device-
related are shown in Table S12 in the Supplementary Appendix.
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times that were faster than those in MR CLEAN16 
and in studies of early-generation interven-
tions.8-10 The median time from arrival in the 
emergency department to groin puncture of 
90 minutes was faster than the 120-minute 
target that is recommended in current multiso-
ciety guidelines.22 In our trial, study sites were 
provided with a prespecified efficiency target of 
performing groin puncture within 70 minutes 
after qualifying imaging, and continuous cen-
tral review encouraged rapid workflow. For 
patients with intravenous t-PA that was initiat-
ed at study centers, groin puncture and stent-
retriever deployment could take place while 
t-PA was infusing.
Several aspects of the treatment and treat-
ment response were distinctive in our study. The 
rate of substantial or complete reperfusion (88%) 
among patients undergoing intracranial inter-
vention was higher in this trial than in previous 
trials. The high reperfusion rate is probably due 
in part to the more homogeneous patient popula-
tion (more occlusions in the first segment of the 
middle cerebral artery and fewer intracranial or 
cervical occlusions of the internal carotid artery) 
and the more homogeneous intervention (an ef-
1.0 3.0 9.0
Stent Retriever +
Intravenous t-PA
Better
Intravenous
t-PA Alone
Better
Sex
Male
Female
Age
≥70 yr
<70 yr
NIHSS score
≤17
>17
Occlusion location
Internal carotid artery
M1
M2
Geographic location
United States
Europe
ASPECTS
6 or 7
8–10
Site of initial administration of t-PA
Study hospital
Outside hospital
Time from onset to randomization
<189 min
≥189 min
Overall
Relative Risk (95% CI)No. of PatientsSubgroup
0.3
1.75 (1.11–2.78)
1.77 (1.07–2.93)
1.70 (1.23–2.33)
1.61 (1.13–2.30)
1.77 (0.91–3.45)
1.62 (1.08–2.42)
1.62 (1.17–2.24)
1.98 (0.73–5.33)
1.63 (1.11–2.39)
1.85 (1.05–3.24)
1.74 (1.23–2.46)
2.04 (0.67–6.21)
2.21 (1.17–4.19)
1.35 (0.41–4.41)
1.49 (1.05–2.11)
1.67 (1.13–2.47)
1.78 (1.03–3.09)
1.61 (1.03–2.50)
P Value
97
93
83
106
110
80
30
133
18
129
62
43
142
126
64
96
94
191
0.78
0.88
0.55
0.87
0.66
0.94
0.87
0.97
Figure 2. Analysis of Functional Independence at 90 Days in Prespecified Subgroups.
Functional independence was defined as a score on the modified Rankin scale of 0, 1, or 2. P values were based on 
the Breslow–Day test for homogeneous odds ratios across subgroups. Squares indicate point estimates for treat-
ment effects, and the size of the square is proportional to the precision of the estimate. Scores on the National In-
stitutes of Health Stroke Scale (NIHSS) range from 0 to 42, with higher scores indicating more severe neurologic 
deficits. The threshold of 17 was the threshold used in stratifying randomization. The Alberta Stroke Program Early 
CT Score (ASPECTS) ranges from 0 to 10, with higher scores indicating a smaller infarct core; a score of 6 or 7 indi-
cates moderate infarct core, and a score of 8 or higher small infarct core. For the time from stroke onset to ran-
domization, the median value was prespecified as the cutoff point for analysis and was found to be 189 minutes. 
M1 denotes first segment of the middle cerebral artery, and M2 second segment of middle cerebral artery.
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fective stent retriever and no other device classes 
and no intraarterial fibrinolytic agent) in this 
trial than in earlier trials. The frequency of func-
tional independence in the intervention group 
was high in our trial (60%) and was greater than 
that observed in MR CLEAN (33%) and similar 
to that observed in the ESCAPE trial (53%) and 
the Extending the Time for Thrombolysis in 
Emergency Neurological Deficits — Intra-Arteri-
al (EXTEND IA) trial (71%).17 The high frequency 
of this outcome probably reflects the earlier start 
of the intervention,23-26 the exclusion of patients 
with large core infarcts on the basis of imag-
ing,27,28 and the greater reperfusion rate in our 
trial, as compared with the other trials.
No significant differences in treatment effect 
were detected across all the prespecified sub-
groups, including such factors as age, sex, degree 
of neurologic deficit, site of occlusion, and size 
of infarct core on qualifying imaging, although 
the moderate sample size limited the power of 
this analysis. We also performed a prespecified 
analysis comparing patients who received intra-
venous t-PA at an outside hospital and were trans-
ferred to a study center for thrombectomy with 
those who received both the intravenous t-PA and 
the endovascular intervention at the study center. 
One third of the patients were treated with intra-
venous t-PA at an outside hospital. These patients 
had less favorable outcomes overall; however, 
their relative benefit from endovascular therapy 
did not differ significantly from that observed in 
patients who received intravenous t-PA at the 
study site (Fig. 2, and Fig. S4 in the Supplemen-
tary Appendix).
The rates of serious adverse events did not dif-
fer significantly between the study groups over-
all or within major organ categories, and no de-
vice-specific serious adverse events were observed. 
The most common nonserious device-specific 
adverse event was transient, intraprocedural vaso-
spasm without clinical sequelae. Rates of symp-
tomatic hemorrhage were low and did not differ 
significantly between the two treatment groups. 
Subarachnoid hemorrhage and intracerebral he-
matomas as assessed radiologically were also un-
common.
Our study has several limitations. First, we 
studied a homogeneous cohort of patients treat-
ed with intravenous t-PA; additional trials are 
needed to delineate the effects of stent-retriever 
therapy in other populations of patients with 
acute ischemic stroke, including those who are 
ineligible for intravenous t-PA, those who pres-
ent more than 6 hours after symptom onset 
(including those who awaken after having had a 
stroke), and those with occlusions in the second 
segment of the middle cerebral artery or the 
posterior circulation. Second, study conduct in-
cluded a continuous quality-improvement pro-
gram to improve endovascular workflow effi-
ciency at the participating sites. Implementation 
of similar quality-improvement programs in rou-
tine care settings,29 as has been done on a broad 
scale for intravenous t-PA,30 would be required 
to ensure similar stent-retriever outcomes in reg-
ular practice. Finally, all the enrolling sites were 
tertiary care centers with established stroke-inter-
vention programs staffed by experienced neuro-
interventionalists. These results may not be 
generalizable to clinical sites without requisite 
neurointerventional expertise.
In conclusion, we found that in patients with 
acute ischemic stroke due to large-vessel occlu-
sion who had small or moderate ischemic cores, 
emergency neurovascular thrombectomy with the 
stent retriever was safe and effective in achieving 
reperfusion and substantially reduced the degree 
of disability and increased the proportion of pa-
tients with functional independence 3 months 
after stroke.
Supported by Covidien.
Disclosure forms provided by the authors are available with 
the full text of this article at NEJM.org.
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